The DOI matches its Crossref record.
Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial
Open accessAbstract
Objective: To evaluate the efficacy and safety of etoricoxib and indomethacin in the treatment of patients with acute gout. Methods: A randomized, double‐blind, active‐comparator study was conducted at 42 sites. A total of 189 men and women (≥18 years of age) who were experiencing an acute attack (≤48 hours) of clinically diagnosed gout were treated for 8 days with etoricoxib, 120 mg/day (n = 103), or indomethacin, 50 mg 3 times a day (n = 86). The primary efficacy end point was the patient's assessment of pain in the study joint (0–4‐point Likert scale) over days 2–5. Safety was assessed by adverse experiences (AEs) occurring during the trial. Results: Etoricoxib demonstrated clinical efficacy comparable to that of indomethacin in terms of the patient's assessment of pain in the study joint. The difference in the mean change from baseline over days 2–5 was –0.08 (95% confidence interval –0.29, 0.13) (P = 0.46), which fell within the prespecified comparability bounds of –0.5 to 0.5. Secondary end points over the 8‐day study, including the onset of efficacy, reduction in signs of inflammation, and patient's and investigator's global assessments of response to therapy, confirmed the comparable efficacy of the two treatments. The etoricoxib‐treated patients had a numerically lower incidence of AEs (43.7%) than did the indomethacin‐treated patients (57.0%) and a significantly lower incidence of drug‐related AEs (16.5% versus 37.2%; P < 0.05). Conclusion: Etoricoxib at a dosage of 120 mg once daily was confirmed to be an effective treatment for acute gout. Etoricoxib was comparable in efficacy to indomethacin at a dosage of 50 mg 3 times daily, and it was generally safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21772 · Cited by 1,536
Zhang, W., Doherty, M., Bardin, T., Pascual, E., Barskova, V, Conaghan, P., Gerster, J., Jacobs, J., Leeb, B., Lioté, F., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.055269 · Cited by 1,407
Khanna, D., Khanna, P. P., Fitzgerald, J. D., Singh, M. K., Bae, S., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21773 · Cited by 728
Dalbeth, N., Choi, H. K., Joosten, L. A. B., Khanna, P. P., Matsuo, H., Perez-Ruiz, F., & Stamp, L. K. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0115-y · Cited by 693
McGettigan, P., & Henry, D. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001098 · Cited by 571
Jordan, K. M., Cameron, J. S., Snaith, M., Zhang, W., Doherty, M., Seckl, J., Hingorani, A., Jaques, R., & Nuki, G. (2007) · Rheumatology · doi:10.1093/rheumatology/kem056a · Cited by 552
Terkeltaub, R. A., Furst, D. E., Bennett, K., Kook, K. A., Crockett, R. S., & Davis, M. W. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27327 · Cited by 536
Update on gout: new therapeutic strategies and options
Terkeltaub, R. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.236 · Cited by 387
Zhang, J., Ding, E. L., & Song, Y. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60015 · Cited by 332
Sivera, F., Andrés, M., Carmona, L., Kydd, A. S. R., Moi, J., Seth, R., Sriranganathan, M., van Durme, C., van Echteld, I., Vinik, O., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203325 · Cited by 262
Management of Gout in the Older Adult
Fravel, M. A., & Ernst, M. E. (2011) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2011.07.004 · Cited by 37
Metadata
- Authors
- Rubin, B. R., Burton, R., Navarra, S., Antigua, J., Londoño, J., Pryhuber, K. G., Lund, M., Chen, E., Najarian, D. K., Petruschke, R. A., Ozturk, Z. E., & Geba, G. P.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2004-02
- Volume
- 50
- Issue
- 2
- Pages
- 598-606
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2071263587
- Cited by
- 188
- References
- 0
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.